Trial Profile

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions
Acronyms ADAPTeR

Most Recent Events

06 Jun 2025 Status changed from active, no longer recruiting to discontinued.
01 Oct 2019 Status changed from recruiting to active, no longer recruiting as per the results presented at the 44th European Society for Medical Oncology Congress.
23 Mar 2018 Planned primary completion date changed from 1 Nov 2016 to 1 May 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com